Growing up together for a healthy future

Actover is an integrated pharmaceutical company with more than 100 products and over 1,000 employees operating in fields of importation, marketing, production and distribution.

Investment in high standard production facilities and qualified personnel has positioned Actover as a partner for under license production in Iran.

FOCUS ON BIOSIMILARS

Biosimilars represent some of the fastest-growing pharmaceutical products in the world. Actoverco's long term strategy includes strengthening.partnerships and investing in this field of medicine.

We are committed to build a leadership position in Iran as well as region. Our biotech plant located in Baharestan industrial zone near Tehran, started production in 2013 with a capacity of 10 million vials and PFS.

OUR PARTNERS

Whether it is for innovative products, branded generics or Biosimilars, we select our partners carefully.

We are the official distributor of 12 world-class pharmaceutical manufacturers. For over 40 years, they have trusted Actover with their products in the ever-changing Iranian market

Our commitment to our partners and our flexibility are the reasons for preserving our partnership throughout mergers, acquisitions, wars and revolution.

We adjust our services to each company depending on their policies. From under license production with Merck, to co branding with Krka or technology transfer in the case of biotech.

Other most recent partners have chosen us because of the capability of our products to comply with MOH policies.

PRODUCTION SITES

Actover is committed to adhere to the regulatory requirements and the highest industry standards.

Our production facilities run by international standards. We have obtained ISO 9001, 14001, OHSAS 18001 and GMP (Good Manufacturing .Practices) certifications, as well as the approval for under license manufacturing of Merck and Krka’s products in Iran

Actover ensures quality by a continuous monitoring of the quality systems, and the application of evolving industry guidelines and regulations.

It includes production lines for pessaries and cream as well as the existing SDF lines

General hazardous plant

Alborz-Zagros is dedicated to the production of general hazardous drugs.

Capacity: 800 million tablets

First general hazardous plant in the country

Good Manufacturing Practice

GMP is a regulatory guideline imposed on all manufacturers of pharmaceuticals to ensure that finished products have the identity, strength, quality and purity they are required to have. GMP describes the methods, the controls, the equipment and facilities that must be put into place for the manufacturing of pharmaceutical products.

ZYLLT

Read all of this leaflet carefully before you start taking
this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.

- If you have any further questions, ask your doctor or your
pharmacist.

- This medicine has been prescribed for you only. Do not
pass it on to others. It may harm them, even if their signs of illness are the
same as yours.

- If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not listed in this leaflet. See section
4.

What is in this leaflet

1. What Zyllt is and what it is used for 4.
Possible side effects

2. What you need to know before you take Zyllt 5. How to store Zyllt

3. How to take Zyllt
6. other information

1. What Zyllt is and what it is used for

Zyllt contains clopidogrel and belongs to a group of medicines
called antiplatelet medicinal products. Platelets are very small structures in
the blood, which clump together during blood clotting. By preventing this
clumping, antiplatelet medicinal products reduce the chances of blood clots
forming (a process called thrombosis).

Zyllt is taken by adults to prevent blood clots (thrombi)
forming in hardened blood vessels (arteries), a process known as
atherothrombosis, which can lead to atherothrombotic events (such as stroke,
heart attack, or death).

You have been prescribed Zyllt to help prevent blood clots
and reduce the risk of these severe events because:

- You have a condition of hardening of arteries (also known
as atherosclerosis), and

- You have previously experienced a heart attack, stroke or
have a condition known as peripheral arterial disease, or

- You have experienced a severe type of chest pain known as
‘unstable angina’ or ‘myocardial infarction’ (heart attack). For the treatment
of this condition your doctor may have placed a stent in the blocked or
narrowed artery to restore effective blood flow. You should also be given
acetylsalicylic acid (a substance present in many medicines used to relieve
pain and lower fever as well as to prevent blood clotting) by your doctor.

- You have an irregular heartbeat, a condition called
‘atrial fibrillation’, and you cannot take medicines known as ‘oral
anticoagulants’ (vitamin K antagonists) which prevent new clots from forming
and prevent existing clots from growing. You should have been told that ‘oral
anticoagulants’ are more effective than acetylsalicylic acid or the combined
use of Zyllt and acetylsalicylic acid for this condition. Your doctor should
have prescribed Zyllt plus acetylsalicylic acid if you cannot take ‘oral
anticoagulants’ and you do not have a risk of major bleeding.

2. What you need to know before you take Zyllt

Do not take Zyllt:

• If you are allergic to clopidogrel or any of the other
ingredients of this medicine (listed in section 6).

• If you have a medical condition that is currently causing
bleeding such as a stomach ulcer or bleeding within the brain.

• If you suffer from severe liver disease.

If you think any of these apply to you, or if you are in any
doubt at all, consult your doctor before taking Zyllt.

Warnings and precautions

If any of the situations mentioned below apply to you, you
should tell your doctor before taking Zyllt:

• if you have a risk of bleeding such as

- a medical condition that puts you at risk of internal
bleeding (such as a stomach ulcer)

- a blood disorder that makes you prone to internal bleeding
(bleeding inside any tissues, organs or joints of your body).

- a recent serious injury

- a recent surgery (including dental)

- a planned surgery (including dental) in the next seven
days

• if you have had a clot in an artery of your brain
(ischaemic stroke) which occurred within the last seven days

• if you have kidney or liver disease

• if you have had an allergy or reaction to any medicine
used to treat your disease.

While you are taking Zyllt:

• You should tell your doctor if a surgery (including
dental) is planned.

• You should also tell your doctor immediately if you
develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura
or TTP) that includes fever and bruising under the skin that may appear as red
pinpoint dots, with or without unexplained extreme tiredness, confusion,
yellowing of the skin or eyes (jaundice) (see section 4 ‘POSSIBLE SIDE
EFFECTS’).

• If you cut or injure yourself, it may take longer than
usual for bleeding to stop. This is linked to the way your medicine works as it
prevents the ability of blood clots to form. For minor cuts and injuries e.g.,
cutting yourself, shaving, this is usually of no concern. However, if you are
concerned by your bleeding, you should contact your doctor straightaway (see
section 4 ‘POSSIBLE SIDE EFFECTS’).

• Your doctor may order blood tests.

Children and adolescents

Do not give this medicine to children because it does not
work.

Other medicines and Zyllt

Tell your doctor or pharmacist if you are taking, have
recently taken or might take any other medicines, including medicines obtained
without a prescription.

Some other medicines may influence the use of Zyllt or vice
versa.

You should specifically tell your doctor if you take

- oral anticoagulants, medicines used to reduce blood
clotting,

- a non-steroidal anti-inflammatory medicine, usually used
to treat painful and/or inflammatory conditions of muscle or joints,

- heparin or any other injectable medicine used to reduce
blood clotting,

If you have experienced severe chest pain (unstable angina
or heart attack), you may be prescribed Zyllt in combination with
acetylsalicylic acid, a substance present in many medicines used to relieve
pain and lower fever. An occasional use of acetylsalicylic acid (no more than
1,000 mg in any 24 hour period) should generally not cause a problem, but
prolonged use in other circumstances should be discussed with your doctor.

Pregnancy and breast-feeding

It is preferable not to take this medicine during pregnancy.

If you are pregnant or suspect that you are pregnant, you
should tell your doctor or your pharmacist before taking Zyllt. If you become
pregnant while taking Zyllt, consult your doctor immediately as it is
recommended not to take clopidogrel while you are pregnant.

You should not breast-feed while taking this medicine.

If you are breast-feeding or planning to breast-feed, talk
to your doctor before taking this medicine. Ask your doctor or pharmacist for
advice before taking any medicine.

Driving and using machines

Zyllt is unlikely to affect your ability to drive or to use
machines.

Zyllt contains lactose

If you have been told by your doctor that you have an
intolerance to some sugars, contact your doctor before taking this medicine.

Always take this medicine exactly as your doctor or
pharmacist has told you. Check with your doctor or pharmacist if you are not
sure.

If you have experienced severe chest pain (unstable angina
or heart attack), your doctor may give you 300 mg of Zyllt (4 tablets of 75 mg)
once at the start of treatment. Then, the recommended dose is one 75 mg tablet
of Zyllt per day to be taken orally with or without food, and at the same time
each day.

You should take Zyllt for as long as your doctor continues
to prescribe it.

If you take more Zyllt than you should

Contact your doctor or the nearest hospital emergency
department because of the increased risk of bleeding.

If you forget to take Zyllt

If you forget to take a dose of Zyllt, but remember within
12 hours of your usual time, take your tablet straightaway and then take your
next tablet at the usual time.

If you forget for more than 12 hours, simply take the next
single dose at the usual time. Do not take a double dose to make up for a
forgotten tablet.

If you stop taking Zyllt

Do not stop the treatment unless your doctor tells you so.
Contact your doctor or pharmacist before stopping.

If you have any further questions on the use of this
medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects,
although not everybody gets them.

Contact your doctor immediately if you experience:

- fever, signs of infection or extreme tiredness. These may
be due to rare decrease of some blood cells.

- signs of liver problems such as yellowing of the skin
and/or the eyes (jaundice), whether or not associated with bleeding which
appears under the skin as red pinpoint dots and/or confusion (see section 2
‘Warnings and precautions’).

- swelling in the mouth or skin disorders such as rashes and
itching, blisters of the skin. These may be the signs of an allergic reaction.

The most common side effect is bleeding.

Bleeding may occur as bleeding in the stomach or bowels,
bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed,
blood in the urine. In a small number of cases, bleeding in the eye, inside the
head, the lung or the joints has also been reported.

If you experience prolonged bleeding when taking Zyllt

If you cut or injure yourself, it may take longer than usual
for bleeding to stop. This is linked to the way your medicine works as it
prevents the ability of blood clots to form. For minor cuts and injuries e.g.,
cutting yourself, shaving, this is usually of no concern. However, if you are
concerned by your bleeding, you should contact your doctor straightaway (see
section 2 ‘Warnings and precautions’).

Other side effects include:

Common side effects (may affect up to 1 in 10 people):
Diarrhoea, abdominal pain, indigestion or heartburn.

Availability is a key concern in Actover. That is why we work with 4 authorized distribution companies in Iran. Maximizing coverage and access to our products is the goal of our experienced professional and team .

We have chosen 4 major distribution companies:

1-Hejrat is the second largest distribution company covering pharmacies and the first covering hospitals

2-Elite Darou is the Actover group owned distribution company, one of the first 100% private pharma distributors in Iran

3-Razi is one of the leading distribution companies in the country

4-Darou Pakh is one of the leading distribution companies in the country

Actover focuses on quality and product safety. We conduct accurate controls and evaluate all our suppliers and manufacturing processes.

Actover is committed not only to all the applicable regulatory requirements, but also to the highest international industry standards. It has successfully passed all GMP audits including GMP audit with PICS observers.

•KRKA-Slovenia has also given GMP approval in the first QA audit in 2011.

•Merck Serono audited Actover factory in 2012 and approved it for production of its solid dosage form products starting with Glucophage 500 tablets.

•Actover’s QC lab has also received accreditation certificate from MOH in 2014 and is regarded as one of a few accredited labs of pharmaceutical companies in Iran.

• Medical department has been awarded ISO9001: 2015 certification: Actoverco scientific and medical department consists of the following units: Clinical trial, Pharmacovigilance and Medical Advisory. To achieve the goals, such as upgrading the quality of provided services, increasing efficiency of the organization and ensuring carrying out our responsibilities, we implemented measures that were audited in accordance with the requirements of ISO9001:2015. The audit was successful and Actoverco Pharmaceuticals managed to obtain the aforementioned certificate in 2017 awarded by SGS company.

We are also committed to the safe use of our product. We believe a safe drug prescription is also our responsibility. We provide comprehensive product knowledge and risk benefit information to the medical community and the patient.

Pharmacovigilance

Pharmacovigilance (PV) system is responsible for monitoring the safety of Actoverco products. Its main aim is to minimize the risks related to drugs used and to maximize their benefits. The vision of the Actoverco Pharmacovigilance Department is to improve nationwide patient safety and wellbeing by reducing the risk of medicines used by patients and the general public.

Drug Information Center

Drug Information Center of Actover Pharmaceutical Company is stablished in October 2015 as a division of the Pharmacovigilance department. The main purposes of DIC encompass rational prescription and use of drugs, increase of awareness, easy access to the authentically most up-to-date, precise, and pertinent information about our company’s drug products as well as to safeguard the health, financial and legal interests of the patients.

If you or your patient experience any unanticipated side effect or have a complaint about a product please report adverse events.

HEALTH RELATED WEBSITES

In Actover, we not only focus on producing and distributing medicines, but also we believe in making health information. Therefore we have created specific magazine & websites, such as:

This is a magazine which is publishing and distributing every month throughout the drugstores, hospitals, clinics and offices of Tehran & some cities in Iran. Each magazine contains recent reliable articles about health & lifestyle. The aim of this distribution is improving general knowledge of people. To verify accessing this magazine on the internet, we have loaded the electronic version in the following address: www.salamsalamt.com

It is a website dedicated for multiple sclerosis patients, where they can find information about the diseases and treatments as well as stories about other patients, news, group gatherings and a forum where they can share their experiences.

To boost the effect of Xenover (Orlistat), we have created a microsite to pair this treatment with healthy routines. This website contains material from recipes to physical activities and tips to change lifestyle habits.

Lifestyles website

Another medicines of Actover Pharmaceutical Company are vitamins and supplements. Since malnutrition and deficiency of micronutrients, minerals and vitamins are the cause of many chronic and threatening public health issues, for the first step, Actover selected and registered the vitamins and supplements from the prestigious company named “Life Style”.

The products of this brand, produced by “Martec Industries” in California, which are one of the highest quality products in the world of pharmaceutical supplements.

Life Style Supplements include Kids Gummies (Multivitamin and Mineral), Stress Formula and Iron, Stress Formula and Zinc (Containing Vitamins and Zinc), Centravite (Daily Multivitamin with Lutein), Advanced Formula (Containing Vitamins, Minerals for people over 50 years of age), omega-3, calcium and vitamin D, and also Triple Joint-Aid (containing glucosamine and chondroitin).

Some products, such as Actopin, Actofenextra, Actocold, and Xenover are among the OTC products of Actover that may also be taken without prescription. For more information on any of these products, you may visit the websites.

OUR RESPONSIBILITY▲

ACTING ETHICALLY

we understand that the pharmaceutical sector is not comparable to any other industry. Ethical behavior is integrated in the core of our business, placing the well being of the patient as our top priority. This is why we are profoundly committed to our responsibility in every aspect of our business

Ethics in research

In all our research, including our clinical studies, we respect the patient and his rights as well as the health care providers.

Ethics in production

Producing high quality and safe drugs is not only a marketing strategy, for us it is our responsibility to provide trustworthy pharmaceuticals.

Ethics in promotional activities

We believe complete and accurate information is a right for healthcare professionals and patients, in order to make the most informed prescription decision. We work hard to promote our products with factual information, in a way to avoid misleading our audiences.

We believe that it is our responsibility to leave the world a better place forthe next generations. That is why we go beyond our legal obligations,

increasing the welfare of the most vulnerable individuals of our society.

We work in three different fronts

Education is the key to building a future. As part of the Dr. Mostafa Naraghi Foundation, we build schools in underprivileged areas. That is why we contribute with scholarship programs and psychological support.

Access to medicine and surgery is every person’s right. We collaborate with different foundations by donating MS and Cancer drugs as well as paying for heart and reconstructive surgery for children.

Food program is a real problem in some of the areas where we work. Some families are unable to offer even one meal a day to their children. We contribute with two initiatives in this direction: The “One meal per day” program that feeds over 1.000 children per day and regular food packages to 300 families so that they can prepare hot food in their homes.

All the Corporate Social Responsibility activities of Actover are coordinated by the Dr. Mostafa Naraghi Foundation.

The Corporate Social Responsibility activities of Actover is coordinating by the Dr. Mostafa Naraghi Foundation. Working with an

independent executive team under the control of the supervisory board.

WE ALSO COLLABORATE WITH:

Chain of Hope
is a French NGO operating in over 30 countries including in Iran. We collaborate by taking in charge surgery costs for young children.

Kahrizak
is a private charitable organization with over 1600 beds where physically handicapped or elderly individuals with no financial resources can live.

NEWS▲

PRESS RELEASE

Press releases:
In this section you can find our latest press releases
If you need more detailed information about Actoverco please read our press kit or contact us at:
press@actoverco.com

The 29th Annual Congress of Iranian Society of Internal Medicine

The 29th annual Congress of Iranian society of Internal medicine was held on 11th to 14th May, 2018 at Razi Conference hall of Iran University of Medical Sciences, and Actover pharmaceutical company attended the congress.

At this annual congress, which was held by the Society of Iranian Internal Medicine, general surgeons, pediatricians, cardiologists, neurologists, emergency medicine and general practitioners attended. Also, Actover pharmaceutical company attended the congress and introduced its products in the internal medicine field, such as Mesalover, Emozul, Mebacto, Letizen, Motilover, Actolucast and Fastover.

It is worth mentioning that this scientific congress was held with the aim of strengthening the communication between internal physicians and exchanging the ideas among them, and also presenting the new scientific achievements.

The first annual congress of the Iranian Psychosomatic Association

The first annual conference of the Iranian Psychosomatic Association was held at the Faculty of Dentistry of Tehran University of Medical Sciences from 9th to 11th May and Actover pharmaceutical company attended this congress.

This annual congress, was held with the aim of increasing the knowledge of psychiatric practitioners and learning the latest achievements in this field. Actover pharmaceutical company attended this congress, and introduced its products in the field of psychiatry and psychosomatic, such as Lyriver, Loxever, Actopentine and Escitover.

The executive secretary of the first annual conference of the Iranian Psychosomatic Association noted that when a patient visits a doctor, the symptoms, physical conditions, and mental state should be examined. On the other hand, when a person comes to a psychiatrist or counselor due to psychiatric problems, in addition to the symptoms and mental state, the patient's physical state should be examined, since body and mind are interrelated and really affect each other.

It should be noted that psychiatrists, neurologists, general practitioners, general surgeons, psychologists, cardiologists, endocrine and metabolism experts, gastroenterologists, oncologists, domestic specialists, gynecologists, and plastic surgeons attended this scientific congress.

5/13/2018The first annual congress of the Iranian...
This annual congress, was held with the aim of increasing th...

The 6th International Congress of Heart Failure

The 6th International Congress of Heart Failure was held at the international conference hall of Shahid Beheshti university on May 9-11, 2018 and Actover pharmaceutical company attended the congress.

This international congress, which was held by the Cardiology Research Center of Shahid Beheshti University of Medical Sciences, Actover pharmaceutical company attended and introduced its products in the field of cardiovascular diseases, such as Metazero, Clotover, Rosurexin, valsacor, Coryol, Zylt, Atorexin , Omacor, Losaver and Amlober.

The Iranian Heart Failure Congress, was held with the aim of presenting the latest scientific advances in the field of prevention and treatment of heart failure, upgrading the knowledge of professors, cardiologists, general practitioners, specialized cardiologists and nurses, and establishing scientific contact between research groups, and Iranian and foreign associations.

5/12/2018The 6th International Congress of Heart...
This Congress was held at the International Conference hall ...

The 25th Congress of Neurology and Electrophysiology

The 25th Congress of Neurology and Electrophysiology, was held at Olympic Hotel from 1st to 4th May, and Actover pharmaceutical company attended this congress.

This congress was held by “The Iranian Neurology Society”. Moreover, at this congress, Actover pharmaceutical company introduced some of its products in the field of neurology such as, Asentra, Yasnal, Lyriver, Actopentine, Loxever, Alventa, Escitover, Quentiax, and also Actovex and Actoferon for treatment of MS.

It should be noted that 24 neurologists from different cities were invited and supported by Actover in order to attend this annual neurology congress.

5/5/2018The 25th Congress of Neurology and Elect...
This congress was held by “The Iranian Neurology Society”

The 14th Iranian Congress of Immunology and Allergy

The 14th Congress of Immunology and Allergy was held at Abu Reyhan conference hall of Shahid Beheshti University from 26th to 28th April, and Actover pharmaceutical company attended the congress.

This congress was held by “The Iranian Society of Immunology and Allergy” in collaboration with Shahid Beheshti University of Medical Sciences. Moreover, Actover pharmaceutical company attended the congress and introduced some of its products such as, Actolucast, Fastover and Letizen to treat asthma and allergy, and also Suprimun and Rituxiver in the field of immunotherapy.

At this annual congress, some domestic and foreign experts and researchers in the field of immunology, including basic immunology, clinical, diagnosis and technology, presented their latest scientific findings.

5/5/2018 The 14th Iranian Congress of Immunology...
This congress was held by “The Iranian Society of Immunology...

End of the year ceremony

One more year passed, a year includes some issues and challenges. However, efficient management with coordination and cooperation of all parts of the company helped Actover to overcome the challenges and obstacles, and make significant achievements and successes.

So, in order to appreciate the efforts of employees, who have promoted the rank of Actover, a ceremony held at the end of the year, and the heads of company and all employees attended.

3/14/2018End of the year ceremony
in order to appreciate the efforts of employees of Actover, ...

In this study, we have conducted a Phase 3,
open label, randomized, parallel, non-inferiority multicenter study comprising
100 trial subjects received “de novo” kidney transplants that were randomly
divided into two groups; Suprimun® (2 g/day) and Cellcept® (2 g/day) (with Cyclosporine and Corticosteroid in both
groups) in order to compare the efficacy, safety, and Mycophenolate (MPA) serum levels between two groups (Sep. 2012 - Oct. 2014) during a 6-month follow up period. Main outcomes
were graft and patient survival. Results revealed that the percentage of patients
experienced biopsy proven acute rejection (BPAR) were 5.3% (n=2) compared to 2.1% (n=1) in Suprimun and Cellcept groups,
respectively (p=0.55), and clinical rejection were suspected for 18.4%
(n=7) in Suprimun group compared to 8.3% (n=4) in Cellcept group (p=0.2). In Suprimun and Cellcept groups, 93.1% and 94.4% of
patients were alive without any need for dialysis, respectively (p=0.23).
There were no differences between study arms in kidney recipients with regard
to creatinine clearancelevel, BUN, GFR, and acute
rejections episodes. In a single day at the end of follow up, no significant
differences were evident in the mean of MPA concentrations at the time points
30 min (702.52 ± 172.7 vs. 781.64 ± 113.4), 75 min (782.84 ± 117.3 vs. 752.51 ±
77.1), and 120 min (410.9 ± 68.1 vs. 364 ± 50.4) after using Suprimun or
Cellcept, respectively. Regarding safety
panel, adverse events and serious adverse events were comparable in both arms. Although
our obtained findings did not show any significant differences between study
arms with respect to primary outcomes, the non-inferiority analyses
collectively showed that Suprimun was not worse than the corresponding reference
treatment (Cellcept) by more than 15% (α=0.025, CI 90%) considering creatinine
serum level, BUN, and GFR upon a 6-month follow up period.

4/26/2015Clinical Safety and Efficacy of Suprimun...
). In Suprimun and Cellcept groups, 93.1% and 94.4% of patie...

Join one of the leading pharmaceutical companies in Iran. Our expanding strategies create exiting career opportunities across the group.

SALES & MARKETING

PRODUCTION

COMMERCIAL AFFAIRS

MEDICAL AFFAIRS

ADMINISTRATION AND ACCOUNTING

Please send your CV to CV@actoverco.com, indicating the position you are applying for in the subject of your CV.

WHY WORK FOR ACTOVERCO

We know that in an ever-changing business environment, human force became the main source of competitive advantage.

By working for Actover you will have the opportunity to develop your skills and progress your career across the range of business areas and functions. You will have the necessary support from managers and colleagues to achieve your professional goals.

Our training programs will help you progress in your field and enhance your expertise.

See how your dedication and hard work would be rewarded in Actover, and also offering you better opportunities in a fast-growing company.